Partnerships & Mergers

The agreement also supports GlobeMed Gulf’s broader strategy of expanding access to high-quality healthcare for its growing base of insured members.

The initiative will support patients with the greatest medical and financial needs by improving access to advanced therapies within a framework aligned with the UAE’s national health insurance system.

The agreement builds on Haleon’s existing use of Microsoft 365 Copilot and broadens the company’s adoption of Microsoft’s AI, cloud and data technologies.

The collaboration aims to turn scientific discoveries into practical healthcare solutions by combining MIT’s research expertise with Abu Dhabi’s expanding life sciences ecosystem.

Under the collaboration, Insilico Medicine will use its proprietary Pharma.AI platform to identify and optimise drug candidates that meet predefined scientific and early development criteria.

Under the partnership, the two organizations will work together to enhance HMC’s Clinical Trials Unit (CTU), strengthen research expertise, and develop initiatives that support the continued growth of Qatar’s healthcare sector.

Verzenios is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor developed by Lilly for the treatment of several forms of breast cancer.

The agreement establishes a formal gateway between Abu Dhabi and California, creating new opportunities for collaboration across research, innovation, investment, and commercialization.

Through the HELM Cluster, the emirate has brought together research institutions, advanced healthcare infrastructure, genomics programs, manufacturing capabilities, and distribution networks within a single ecosystem.

The agreement was formalized by Ali El Ghamrawy, Chairperson of the Egyptian Drug Authority, and James Peter Komie, Chairperson of the Pharmacy Board of Sierra Leone, in the presence of Sierra Leone’s Ambassador to Egypt, Sadiq Sillah.